Model Innovation in Parkinson’s disease drug development: linking Quantitative Systems Pharmacology to the patient voice
Objective: There is a growing sense of urgency to integrate the voice of the patient in drug development in Parkinson’s disease (PD). Public private partnerships…A Case of Autoimmune Orofacial Dyskinesia associated with Striational Antibody
Objective: This is a case of steroid-responsive, autoimmune orofacial dyskinesia associated with extremely elevated striational [striated muscle] antibody. We present this instructive case to add…Facial dyskinesias mimics a new-onset status epilepticus in a patient with autoimmune encephalitis
Objective: Movement disorders in autoimmune encephalitis are common. The mainly differential in this case are epileptic movements, as the new onset status epilepticus (NOSE). An…PSYCHODYNAMIC THERAPY GROUPS FOR RELATIVES AND CAREGIVERS IN THE CONTEXT OF A PD PROGRAM
Objective: Evaluate outcome of psychodynamic-oriented psychological support for relatives and caregivers in an Interdisciplinary program for non-pharmacological treatment with PD. Background: From the beginning of…Happy to be home: Satisfaction with interdisciplinary home visits among individuals with advanced Parkinson’s Disease and their caregivers
Objective: To compare satisfaction with medical care among people with advanced Parkinson’s Disease (PD) and their caregivers at baseline (best usual care in a tertiary…Effect of physical exercises on gait speed in patients with Parkinson’s disease
Objective: To verify the effect of the application of physical exercises with a dual task on gait speed and the occurrence of falls in people…The EPSILON (Early ParkinSon wIth L-dopa/DDCi and OpicapoNe) study in early Parkinson’s disease: design and rationale of a phase III, double-blind, randomized, placebo-controlled study
Objective: This study aims to explore the potential of opicapone (OPC) to enhance the clinical benefit of levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCi) in patients with…Evaluating Engagement of ABBV-0805, an Anti-Alpha-Synuclein Monoclonal Antibody to Physiological and Pathological Forms of Alpha-Synuclein for Phase 2 Dose Selection: A PBPK Modeling and Simulation Approach
Objective: To develop a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model to assist in the dose and dosing regimen selection of ABBV-0805 for Phase 2 studies. Background:…The Hauser Diary knowledge test as a tool to improve Rater Training Programs in Parkinson’s disease clinical trials
Objective: To identify the areas with specific training needs for Rater Training Programs (RTP) on the Hauser Diary in Parkinson’s disease (PD) clinical trials Background:…Apathy Following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Randomized Controlled Trial
Objective: To determine frequency and predictors of improvement or worsening of apathy in participants receiving bilateral subthalamic deep brain stimulation (STN-DBS) for the treatment of…
- « Previous Page
- 1
- …
- 116
- 117
- 118
- 119
- 120
- …
- 132
- Next Page »